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Relationship of Arterial Stiffness Index and Pulse Pressure With
Cardiovascular Disease and Mortality
M. Abdullah Said, BSc;* Ruben N. Eppinga, MD;* Erik Lipsic, MD, PhD; Niek Verweij, PhD; Pim van der Harst, MD, PhD
Background-—Vascular aging results in stiffer arteries and may have a role in the development of cardiovascular disease (CVD).
Arterial stiffness index (ASI), measured by ﬁnger photoplethysmography, and pulse pressure (PP) are 2 independent vascular aging
indices. We investigated whether ASI or PP predict new-onset CVD and mortality in a large community-based population.
Methods and Results-—We studied 169 613 UK Biobank participants (mean age 56.8 years; 45.8% males) who underwent ASI
measurement and blood pressure measurement for PP calculation. MeanSD ASI was 9.303.1 m/s and meanSD PP was
50.9813.2 mm Hg. During a median disease follow-up of 2.8 years (interquartile range 1.4–4.0), 18 190 participants developed
CVD, of which 1587 myocardial infarction (MI), 4326 coronary heart disease, 1192 heart failure, and 1319 stroke. During a median
mortality follow-up of 6.1 years (interquartile range 5.8–6.3), 3678 participants died, of which 1180 of CVD. Higher ASI was
associated with increased risk of overall CVD (unadjusted hazard ratio 1.27; 95% conﬁdence interval [CI], 1.25–1.28), myocardial
infarction (1.38; 95% CI, 1.32–1.44), coronary heart disease (1.31; 95% CI, 1.27–1.34), and heart failure (1.31; 95% CI 1.24–1.37).
ASI also predicted mortality (all-cause, CVD, other). Higher PP was associated with overall CVD (1.57; 95% CI, 1.55–1.59),
myocardial infarction (1.48; 95% CI, 1.42–1.54), coronary heart disease (1.47; 95% CI, 1.43–1.50), heart failure (1.47; 95% CI,
1.40–1.55), and CVD mortality (1.47; 95% CI, 1.40–1.55). PP improved risk reclassiﬁcation of CVD in a non–laboratory-based
Framingham Risk Score by 5.4%, ASI by 2.3%.
Conclusions-—ASI and PP are independent predictors of CVD and mortality outcomes. Although both improved risk prediction for
new-onset disease, PP appears to have a larger clinical value than ASI. ( J Am Heart Assoc. 2018;7:e007621. DOI: 10.1161/
JAHA.117.007621.)
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A s the arterial system ages, the large elastic arteriesundergo progressive luminal dilatation, thickening of the
arterial wall, increased deposition of collagen, and combined
fragmentation and degeneration of elastin.1 The result of
these changes is stiffening of the arteries and consequent
increase in pulse-wave velocity (PWV), which is used to assess
arterial stiffness. Increased arterial stiffness can cause
isolated systolic hypertension, which increases pulse pressure
(PP). Arterial stiffness and PP are independent measures of
vascular aging.2 PP is strongly related to adverse outcomes
such as coronary heart disease (CHD), and cardiovascular
events in hypertensive patients,3 elderly,4 and the general
population.5 Several studies have observed carotid-femoral
(aortic) PWV, which is considered the criterion standard of
arterial stiffness, to be strongly related to risk factors such as
atherosclerosis,6 hypertension,7 metabolic syndrome,7 dia-
betes mellitus,7 and future cardiovascular disease (CVD)
events,8 including CHD, stroke,8 and all-cause mortality.8
Arterial stiffness index (ASI) is a convenient and noninvasive
method to measure arterial stiffness by using infrared light
(photoplethysmography) to record the volume waveform of
the blood in the ﬁnger. The shape of the waveform is directly
related to the time it takes for the pulse wave to travel
through the arterial tree. These tools might be of interest to
quickly estimate CVD risk.9,10
In this study we investigated the association of vascular
aging as indicated by ASI and PP with CVD risk factors, CVD
events, and mortality in 169 613 participants from UK
Biobank.
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The data from the UK Biobank resource are available for other
researchers following an approved research proposal.11 The
UK Biobank study design and population have been described
in detail elsewhere.12 In brief, UK Biobank is a large
community-based prospective study in the United Kingdom
that recruited >500 000 participants aged 40 to 69 years old
with the aim of improving prevention, diagnosis, and
treatment of a plethora of illnesses including cancer, diabetes
mellitus, stroke, and heart diseases. A total of 190 077
participants had an ASI measurement during their ﬁrst or 1 of
the follow-up visits. We analyzed data from 169 829 partic-
ipants who had an ASI assessment at their ﬁrst visit to the
assessment centers in England and Wales. No ASI assess-
ments were performed for participants from Scotland. All
participants gave informed consent for the study via a touch-
screen interface that required agreement for all individual
statements on the consent form as well as the participant’s
signature on an electronic pad.13 In this process all partic-
ipants gave informed consent for data linkage as 1 statement
requested consent for access to medical and other health-
related records, the long-term storage and use of this and
other information about the participants, also after incapacity
or death, for health-related research. The UK Biobank consent
form is available at: http://www.ukbiobank.ac.uk/wp-conte
nt/uploads/2011/06/Consent_form.pdf. UK Biobank has
approval from the institutional review boards, namely, the
North West Multi-centre Research Ethics Committee for the
UK, from the National Information Governance Board for
Health & Social Care for England and Wales, and from the
Community Health Index Advisory Group for Scotland.14
Ascertainment of ASI
PWV for ASI assessment was measured during the ﬁrst visit to
the assessment center using the PulseTrace PCA2 (CareFu-
sion, San Diego, CA) (Field-ID 21021) in 169 829 participants
from 2009 until 2010. The PulseTrace PCA2 uses ﬁnger
photoplethysmography to obtain the pulse waveform during a
10- to 15-s measurement using an infrared sensor clipped to
the end of the index ﬁnger. The measurement was repeated
on a larger ﬁnger or on the thumb if less than two thirds of the
waveform was visible on the display of the PulseTrace PCA2
device, or if the waveform did not stabilize within 1 minute
after clipping the infrared sensor to the end of the index
ﬁnger.15 The shape of the waveform is directly related to the
time it takes for the pulse wave to travel through the arterial
tree.10,15 The standing height (shoeless) was measured using
a Seca 202 height measure and was manually entered into
the assessment center software by a UK Biobank staff
member. The software immediately alerted the staff member
when he/she entered impossible or implausible values and
was asked to correct it.13 Height (meters) was divided by the
time between the peaks of the pulse waveform to obtain the
ASI in m/s.15 This method has been validated by comparing it
with carotid-femoral PWV in 3 independent studies that
concluded both measurements are highly correlated and that
ASI is a simple, inexpensive, rapid technique that requires no
training and is operator independent.9,10,16
Ascertainment of Cardiovascular Events
The prevalence and incidence of cardiovascular risk factors,
conditions and events were captured through self-reported
data collected at the assessment center using a questionnaire
and a verbal interview. Diagnoses were additionally captured
using the “Spell and Episode” category from the Hospital
Episode Statistics records. This category contains main and
secondary diagnoses, coded according to the International
Classiﬁcation of Diseases Ninth Revision (ICD-9) and 10th
Revision (ICD-10),17 made during hospital inpatient stay. The
main diagnosis is taken to be the main reason for the hospital
admission, while secondary diagnoses are more often
contributory or underlying conditions. Furthermore, we used
surgical procedures that were recorded according to the
Ofﬁce of Population, Censuses and Surveys: Classiﬁcation of
interventions and Procedures, version 4 coding.18 We used
both the main and secondary diagnoses for recording
prevalent and incident risk factors, conditions, and events.
Incidence cases based on self-reported diagnoses during
follow-up visits were included only if there were no events
recorded according to ICD-9/ICD-10/Ofﬁce of Population,
Censuses and Surveys: Classiﬁcation of interventions and
Procedures and only if the participant did not report this in the
previous visit. Date of event was then deﬁned as reported age
Clinical Perspective
What Is New?
• Analyses of the largest arterial stiffness index data set
(n=169 613) to date indicated that it was an independent
predictor of incident cardiovascular disease and all-cause
mortality.
• Arterial stiffness index improved the 5.9-year risk prediction
model of incident cardiovascular events by 2.3% when
added to the Framingham Risk Score.
• Pulse pressure improved the 5.9-year risk prediction model
by 5.4% when added to the Framingham Risk Score.
What Are the Clinical Implications?
• Pulse pressure appears to have more added value than
arterial stiffness index to improve the risk classiﬁcation of
incident cardiovascular disease.
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of diagnosis (when available) or the median date between the
visit of the ﬁrst self-reported diagnosis and the previous visit.
Follow-up for new-onset CVD, myocardial infarction (MI), CHD,
heart failure (HF), stroke, and death because of these new-
onset cardiovascular conditions was from inclusion until
March 31, 2015 for participants from England and until
February 28, 2015 for participants from Wales. Please see
Table S1 for the deﬁnitions used.
Ascertainment of Mortality
Participant follow-up for mortality started at inclusion in the
UK Biobank study and was censored on January 31, 2016 for
all participants from England and Wales. The information
about cause of death was obtained from the National Health
Service Information Centre. Detailed information about the
linkage procedure is available online at http://biobank.ctsu.
ox.ac.uk/crystal/refer.cgi?id=115559.
Blood Pressure Measurements and PP and Mean
Arterial Pressure Calculation
Systolic and diastolic blood pressure (Field ID 4079, 4080)
were measured twice at the assessment center using an
automated blood pressure device (Omron 705 IT electronic
blood pressure monitor; OMRON Healthcare Europe B.V.
Kruisweg 577 2132 NA Hoofddorp), or manually (Field ID 93,
94) using a sphygmomanometer with an inﬂatable cuff in
combination with a stethoscope if the blood pressure device
failed to measure the blood pressure or if the largest inﬂatable
cuff of the device did not ﬁt around the participant’s arm.19 All
measurements were performed while the participant was
sitting in a chair and were carried out by nurses trained in
performing blood pressure measurements.19 During the ﬁrst
measurement nearly all participants (169 529) had blood
pressure measurements using the automated blood pressure
device. All had a second automated blood pressure measure-
ment, except 153 individuals who did not have a second
measurement. Manual sphygmomanometer blood pressure
measurements during the ﬁrst measurement were performed
on 84 participants (0.05% of the total population). Of these,
11 participants had no second measurement and all others
had a second manual blood pressure measurement. Multiple
available measurements for 1 individual were averaged. PP
was calculated by subtracting the (average) diastolic from the
(average) systolic blood pressure value. Mean arterial pres-
sure (MAP) was calculated by dividing the PP by 3 and adding
this value to the diastolic blood pressure. The Omron 705 IT
blood pressure monitor has satisﬁed the Association for the
Advancement of Medical Instrumentation SP10 standard and
has been validated according to the British Hypertension
Society protocol, with an overall “A” grade for both systolic
and diastolic blood pressure measurements.20 However, since
automated devices tend to measure higher systolic blood
pressures than manual sphygmomanometers, we adjusted
both systolic and diastolic blood pressures that were
measured using the automated device using algorithms by
Stang et al.21 For systolic blood pressure we used the
following algorithm: 3.3171+0.92019level (systolic blood
pressure in mm Hg)+6.02469sex (male=1; female=0). For
diastolic blood pressure we used: 14.5647+0.80929level
(diastolic blood pressure in mm Hg)+2.01089sex (male=1;
female=0). These adjusted blood pressure values were used
for all calculations, including the PP and MAP calculations.
Statistical Analysis
Data are expressed as median (interquartile range) or as
meanSD for quantitative variables and as counts with
percentages for discrete and categorical variables. Partici-
pants with ASI values below or above 4 SDs of the mean were
excluded, as well as participants with incorrect inclusion
dates and those younger than 40 years old, as this last group
was considered less likely to undergo an event during follow-
up.
To evaluate whether ASI and PP increased with age, we
performed regression spline models with 95% conﬁdence
intervals per 5 years of age for females and males separately.
We examined the effect of traditional cardiovascular risk
factors on ASI and PP using unadjusted linear regression
analyses and found all risk factors (sex, age, body mass index
[BMI], MAP, diabetes mellitus, and smoking) were associated
with both measures. We considered these risk factors in
multivariable Cox regression models. We used up to 4
summative models. Model 1: Unadjusted; Model 2: Adjusted
for age and sex; Model 3: Model 2+MAP, diabetes mellitus,
smoking, and BMI; Model 4: Model 3+history of CVD, MI,
CHD, HF, and stroke. To examine the predictive value of ASI
and PP for new-onset CVD, MI, CHD, HF, and stroke, we
performed Cox regression analyses using Model 1 to 3.
Participants with a history of CVD, MI, CHD, HF, or stroke,
were excluded from the respective analyses. To examine the
relationship between ASI and PP with all-cause, CVD, and non-
CVD mortality, we applied Model 1 to 4. For the Cox
regression analyses, we reported hazard ratios and 95%
conﬁdence intervals.
Kaplan–Meier failure curves were plotted for outcomes
associated with ASI or PP. Because older individuals tend to
have more CVD events and die sooner, the use of single ASI
and PP distributions for the entire study sample would result
in a greater proportion of older participants to undergo
events, in comparison to the smaller proportion of younger
participants with fewer events. To improve the balance of
these proportions, we stratiﬁed for deciles of age at ASI and
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PP measurement. Age decile cut points for men were at 44,
49, 52, 56, 59, 61, 63, 65, and 67 years. For women the
cut points were at 44, 48, 52, 55, 58, 60, 62, 64, and
67 years. We then determined ASI and PP distributions for
each decile, separately for ASI and PP and by sex.
Participants with ASI and PP measurements below and
above the median of their respective sex- and age-speciﬁc
deciles were pooled together and compared. Log-rank
testing was performed to estimate the statistical difference
between the medians.
Harrell’s C-indices, a generalization of the area under the
receiver operating characteristics curve for data from Cox
regression analyses, were computed for Model 3 for disease
and Model 4 for mortality outcomes, both with and without
additional adjustment for ASI or PP. Postestimation analysis
was used to determine whether ASI or PP independently
predicted outcomes compared with the traditional risk
factors. We further investigated the possible clinical impact
of ASI and PP measurements in UK Biobank by performing
reclassiﬁcation analyses using the net reclassiﬁcation
improvement (NRI) and the integrated discrimination
improvement.22 For the reclassiﬁcation analyses, we used
a non–laboratory-based Framingham Risk Score (FRS) in
which BMI is used instead of cholesterol.23 Because the FRS
calculates 10-year risk and we had a maximum of
5.92 years of follow-up, we divided the FRS risk estimates
by 1.69 to represent the 5.92-year risk. Individuals were
classiﬁed into <5%, 5% to 15%, and >15% risk categories.
P<0.05 was considered statistically signiﬁcant. All analyses
were performed using Stata version 14 (StataCorp. 2015;




We studied 169 613 individuals (45.8% males; average age
56.8 years old) participating in UK Biobank and of whom PP
and ASI had been measured. The sample selection strategy is
presented in Figure S1 and baseline characteristics are
presented in Table 1. In total, 333 042 UK Biobank partici-
pants were excluded from the analyses. Baseline character-
istics of the excluded participants are shown in Table S2.
Ethnic backgrounds of included and excluded participants
(both >90% white) are provided in Table S2. The most
common risk factor was past or current smoking, followed by
hypertension. CHD was diagnosed most often (n=4326),
followed by MI (n=1587), stroke (n=1319), and HF (n=1192).
The overall mean ASI was 9.303.1 m/s and mean PP was
50.9813.2 mm Hg. ASI and PP were weakly correlated with
each other (R2=0.01; P<0.001). Both increased with
advancing age (R2=0.04 for ASI; R2=0.17 for PP; both
P<0.001, Figure S2). Multiple cardiovascular risk factors
(increased BMI, hypertension, MAP, diabetes mellitus, and
smoking) were associated with ASI and PP (Table 1). Heart
rate was positively associated with ASI and negatively
associated with PP (Table 1).
ASI and PP Are Associated With New-Onset
Cardiovascular Events
The median follow-up duration for new-onset disease events
was 2.8 years (interquartile range 1.4–4.0). Kaplan–Meier
failure curves for CVD divided by the median ASI and PP
are shown in Figure. Curves for MI, CHD, and HF divided by
the median ASI are shown in Figure S3 and curves for MI,
CHD, and HF divided by the median PP in Figure S4. Log-
Rank testing showed a difference between below and above
the median ASI and PP for most diseases. HF showed no
difference between below and above the median ASI. In
total, during a maximum of 5.9 years of follow-up, CVD was
diagnosed in 18 190 individuals. Cox regression analyses
showed that both increased ASI and PP were associated
with increased risk for CVD, MI, CHD, HF, and stroke
(Table 2). Adjustment for age and sex did not alter the
associations (Table 2). Additional adjustment for CVD risk
factors (MAP, diabetes mellitus, smoking, and BMI) resulted
in loss of the associations between ASI and PP with stroke
and lead to small effect sizes for most outcomes (Table 2).
Additional adjustment for PP did not affect the associations
between ASI with the disease outcomes, nor did additional
adjustment for ASI affect the association between PP with
disease outcomes (Table S3). We also plotted the risk of
quintiles of ASI and PP for overall CVD adjusted for the
third model and observed semilinear increases in risk
(Figure S5).
Addition of ASI to traditional risk factors increased C-
indices for MI and CHD, independent of additional adjustment
for PP (Table S4). Addition of PP to traditional risk factors
increased C-indices for CVD and CHD independently of
adjustment for ASI, but it did not increase C-indices for MI or
stroke. The NRI showed improvement (2.3%; 95% conﬁdence
interval, 2.0–2.6; P<0.001) in reclassiﬁcation when ASI was
added to the FRS (Table 3). Also the integrated discrimination
improvement was improved with an estimate of 0.0008
(P<0.001). When PP was added to the FRS, the NRI showed
an improvement of 5.4% (95% conﬁdence interval, 4.9–5.8;
P<0.001; Table 4) and the integrated discrimination improve-
ment was estimated at 0.006 (P<0.001). We calculated the
cutoff values using Youden’s index (indicating the value at
which the measure has highest sensitivity and speciﬁcity) of
ASI and PP for overall CVD at 9.21 m/s and 51.23 mm Hg,
respectively.
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ASI and PP are Associated With Mortality
Median follow-up for mortality was 6.1 years (interquartile
range 5.8–6.3). In total, 3678 participants died, of which
1180 participants of CVD. Kaplan–Meier failure curves for all-
cause, CVD, and non-CVD mortality divided by the age- and
sex-speciﬁc median ASI are shown in Figure S6 and a curve
for CVD mortality divided by the median PP in Figure S7. Log-
rank testing showed a difference for all mortality outcomes,
except CVD mortality, which showed no difference between
the ASI values. In univariate Cox regressions we observed that
higher ASI and PP were associated with increased risk for all
mortality outcomes (Table 5). The association between ASI
with increased risk of all mortality outcomes persisted when
adjusted for traditional risk factors and history of CVD, MI,
CHD, HF, or stroke (Table 5). To investigate whether the
association between ASI and non-CVD mortality was driven by
cancer mortality or other causes, we divided non-CVD
mortality into cancer mortality and death by other causes
(non-CVD/noncancer). ASI was associated with both cancer
mortality and non-CVD/noncancer mortality, also after
adjustment for all factors mentioned above (Table S5). The
associations of PP with all-cause and non-CVD mortality were
less strong (Table 5).
To determine whether ASI is a predictor for all-cause, CVD,
and non-CVD mortality independently of PP, we adjusted the
largest signiﬁcant ASI Cox regression models for PP, which
did not affect any of the associations (Table S6). Similarly,
adjusting the PP Cox regression models for ASI did not affect
the PP associations either. Postestimation C-indices for all-
cause mortality were improved after ASI was added to the
traditional risk factors and history of disease, independent of
adjustment for PP (Table S4). C-indices for CVD mortality did
not improve when PP was added to the traditional risk factors
and history of disease (Table S4).
In the literature there is ongoing debate whether PP24 and
especially aortic PWV25,26 measurements should be adjusted
for heart rate. For this reason we performed sensitivity analyses
adjusting the largest signiﬁcant PP and ASI models for heart
rate, but this did not affect our conclusions (Table S7).
Discussion
We studied 2 independent measures of vascular aging,2 ASI
and PP, in relation to CVD events and mortality in 169 613
participants of UK Biobank. In the largest sample size
available to date, we demonstrated that ASI was an indepen-
dent predictor of new-onset CVD outcomes and mortality.
Furthermore, we have shown that PP was an independent
predictor of CVD, MI, CHD, HF, and CVD mortality. PP
improved C-indices of CVD and CHD, but not of MI, stroke,
and CVD mortality, compared with traditional risk factors. PP
added to the nonlaboratory FRS improved the NRI twice as
much compared with ASI.
Associations With CVD
We found that both increased ASI and PP were associated
with an increased risk of developing CVD. The predictive value
Table 1. Baseline Characteristics of the Study Population (n=169 613) and Unadjusted Associations With ASI and PP
Characteristics MeanSD or n (%)
ASI PP
b (95% CI) P Value b (95% CI) P Value
Males 77 708 (45.8) 0.39 (0.38–0.40) <0.001 0.46 (0.45–0.47) <0.001
Age, y 56.778.16 0.03 (0.03–0.03) <0.001 0.05 (0.05–0.05) <0.001
Heart rate, bpm* 68.7211.01 0.08 (0.08–0.08) <0.001 0.05 (0.06 to 0.05) <0.001
Body mass index, kg/m2* 27.464.82 0.24 (0.23–0.25) <0.001 0.18 (0.17–0.19) <0.001
Blood pressure, mm Hg*
Systolic 132.9217.78 0.10 (0.10–0.10) <0.001 0.50 (0.50–0.50) <0.001
Diastolic 81.948.37 0.24 (0.24–0.25) <0.001 0.39 (0.39–0.40) <0.001
Mean arterial 98.9410.65 0.19 (0.19–0.20) <0.001 0.63 (0.63–0.63 <0.001
Hypertension 52 885 (31.2) 0.23 (0.22–0.24) <0.001 0.56 (0.55–0.57) <0.001
Diabetes mellitus 10 267 (6.1) 0.19 (0.17–0.21) <0.001 0.31 (0.29–0.33) <0.001
Hyperlipidemia 34 723 (20.5) 0.23 (0.22–0.24) <0.001 0.40 (0.39–0.41) <0.001
Past or current smoker 100 590 (59.3) 0.14 (0.13–0.15) <0.001 0.06 (0.05–0.07) <0.001
Means with SD or counts with percentages are given per characteristic. The b coefﬁcients with 95% conﬁdence interval (CI) are estimated using ASI per SD change in m/s and PP per SD
change in mm Hg. The b coefﬁcients show the extent to which the baseline characteristics have an effect on ASI and PP. ASI indicates arterial stiffness index; bpm, beats per minute; PP,
pulse pressure.
*The b coefﬁcients for heart rate, body mass index, and blood pressure are given per 10 units change, respectively.
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of ASI and PP can be considered a reﬂection marking the
(patho)physiological function of the cardiovascular system.
Stiffer arteries allow the pressure wave in the arterial tree to
travel faster, causing systolic rather than diastolic augmen-
tation of the reﬂected pressure wave. Systolic augmentation
increases PP and left ventricular load, which in turn can lead
Figure. Shown are cumulative new-onset cardiovascular disease in (%) divided by the median ASI (A) and the median PP (B). All curves were
adjusted for age and sex. Log-Rank testing shows signiﬁcant differences for A and B. ASI indicates arterial stiffness index; PP, pulse pressure.










Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
ASI
Model 1 1.27 (1.25–1.28) <0.001 1.38 (1.32–1.44) <0.001 1.31 (1.27–1.34) <0.001
Model 2 1.11 (1.10–1.13) <0.001 1.17 (1.11–1.22) <0.001 1.11 (1.08–1.14) <0.001
Model 3 1.04 (1.03–1.06) <0.001 1.13 (1.07–1.18) <0.001 1.08 (1.05–1.11) <0.001
PP
Model 1 1.57 (1.55–1.59) <0.001 1.48 (1.42–1.54) <0.001 1.47 (1.43–1.50) <0.001
Model 2 1.32 (1.30–1.34) <0.001 1.17 (1.11–1.23) <0.001 1.15 (1.12–1.19) <0.001







Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
ASI
Model 1 1.31 (1.24–1.37) <0.001 1.25 (1.19–1.32) <0.001
Model 2 1.09 (1.03–1.15) <0.01 1.08 (1.02–1.14) <0.01
Model 3 1.07 (1.01–1.13) 0.02 1.05 (1.00–1.11) 0.07
PP
Model 1 1.47 (1.40–1.55) <0.001 1.47 (1.40–1.54) <0.001
Model 2 1.10 (1.04–1.16) <0.01 1.16 (1.10–1.22) <0.001
Model 3 1.21 (1.13–1.30) <0.001 1.05 (0.98–1.13) 0.17
Hazard ratios (HR) with 95% conﬁdence interval (CI) estimated using ASI per SD change in m/s and PP per SD change in mm Hg are shown per model for incident CVD, myocardial
infarction, coronary heart disease, heart failure, and stroke. Model 1: univariate (unadjusted). Model 2: adjusted for age and sex. Model 3: Model 2+mean arterial pressure, diabetes
mellitus, smoking, and body mass index. ASI indicates arterial stiffness index; CHD, coronary heart disease; CVD, cardiovascular disease; PP, pulse pressure.
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to cardiac hypertrophy.27 In addition, ischemia of the left
ventricle could also occur through decreased aortic pressure
during diastole causing reduced coronary ﬁlling and thereby
reduced myocardial perfusion.27,28
In our study we found a positive association between
overall CVD events and ASI whereby the risk increased with
6% per SD change. This association is in line with previous,
smaller observations.8,29 Both reported a higher risk (6.15%
versus 1.6% risk per year) of developing CVD per SD increase
in aortic PWV. This difference in effect size might be
attributable to differences in baseline characteristics. For
example, participants of the study by Mitchell et al29 were
recruited from 1998 to 2001 and were on average 6.2 years
older. The participants of the studies in the meta-analysis of
Vlachopoulos et al8 were recruited from 1980 to 2005 and
were on average 2.4 years older than our participants.
The association between PP and CVD incidence was
previously reported by Blacher et al30 in older (average 67–
72 years) hypertensive patients who had a 17% increased
risk of CVD per 10 mm Hg higher PP. The risk of developing
CVD in this cohort of hypertensive subjects is higher than
the risk observed in our presumably healthier community-
based population, which was 3.8% when estimated per
10 mm Hg higher PP (1 SD in our population equals
13.2 mm Hg difference in PP). As noted before, ASI and
PP are independent measures of vascular aging; also in our
study the correlation between ASI and PP was weak. ASI and
PP likely do not reﬂect the same properties or character-
istics of the vasculature. However, improvement in NRI was
observed when ASI and PP were added to the non–
laboratory-based FRS, indicating both ASI and PP may aid
the risk prediction of overall CVD. The improvement of the
NRI by addition of ASI was low (2.3%), whereas the
improvement of the NRI by addition of PP was much larger
(5.4%), indicating a superior possible clinical applicability of
PP compared with ASI. The NRI possibly better reﬂects the
added clinical value of ASI and PP to the risk prediction than
the C-indices, which for each end point were similar until the
third decimal. We also performed sensitivity analyses in
subgroups and found PP was modestly better than ASI at
predicting mainly overall CVD in, for example, women,
participants with diabetes mellitus, and both young and old
participants (Tables S8 through S12). ASI was better at
predicting overall CVD in men and all-cause mortality in
women, nondiabetics, and young participants (≤56.8 years).
ASI and PP were not different in subgroups of hypertension
and FRS (Tables S9 and S11). However, also in these
additional analyses the C-indices were very similar. The
signiﬁcant differences in C-indices between different models
of the main- and subgroup analyses may be attributable to
Table 3. Reclassiﬁcation of Predicted 5.9 Years Risk of New-Onset CVD Events With the Addition of Arterial Stiffness Index to a
Non–Laboratory-Based Framingham Risk Score
Model Without ASI
Model With ASI Risk Reclassiﬁcation
<5% 5% to 15% ≥15% Total Higher Lower
<5%
Persons included 14 376 1536 0 15 912
No. of events 352 68 0 420 68 NA
No. of nonevents 14 024 1468 0 15 492 1468 NA
5%–15%
Persons included 3450 70 618 937 75 005
No. of events 148 6673 205 7026 205 148
No. of nonevents 3302 63 945 732 67 979 732 3302
≥15%
Persons included 0 2600 48 054 50 654
No. of events 0 224 10 520 10 744 NA 224
No. of nonevents 0 2376 37 534 39 910 NA 2376
Total
Persons included 17 826 74 754 48 991 141 571
No. of events 500 6965 10 725 18 190 273 372
No. of nonevents 17 326 67 789 38 266 123 381 2200 5678
NRI 2.3% (95% CI, 2.0–2.6; P<0.001)
ASI indicates arterial stiffness index; CI, conﬁdence interval; CVD, cardiovascular disease; NA, not applicable; NRI, net reclassiﬁcation improvement.
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the large sample size and does not represent a difference
that is clinically relevant.
Besides ﬁnding an association between ASI and PP with
overall CVD, we observed associations between ASI and PP
with several speciﬁc disease outcomes. Both ASI and PP
were associated with MI and CHD in our community-based
population. In aortic PWV studies, MI was often included in
the deﬁnition of outcome variables such as overall CVD
events or CHD, but not investigated as an individual
outcome as has been done in this study. These previous
studies show an association between aortic PWV and
CHD,8,31–33 as is shown here as well. Our results are
consistent with previous PP studies that reported associa-
tions with both incident MI3 and CHD34 after adjustment for
traditional CVD risk factors in a hypertensive and commu-
nity-based cohort, respectively.
The association between aortic PWV with HF is inconsis-
tent across studies.32,35 We found an association between ASI
and HF after adjustment for traditional CVD risk factor but it
had little discriminating power. We found a strong association
between PP and HF, similar to 2 previous studies that found
PP independently predicted chronic HF in the Framingham
Heart Study population36 and an elderly population.37
Finally, neither ASI nor PP was associated with stroke in our
population in survival models after adjustment for MAP. The
association between arterial stiffness measured by carotid-
femoral PWV index and stroke, which was also adjusted for
MAP, has, however, been described previously.31 Also the
associations of PPwith stroke are inconsistent with earlier work
in older people with isolated systolic hypertension, where they
found an 11% increased risk per 10 mm Hg higher PP, but also
showed that MAP increased risk of stroke.38 However, a later
study in uncontrolled hypertensive subjects found, similar to
this study, that the relationship between PP and stroke was
dependent onMAP,39 indicating that MAPmay be a confounder
in the association between PP and stroke.
Associations With Mortality
In the present work we found that ASI was associated with all-
cause, CVD, and non-CVD mortality, although no statistical
difference between CVD mortality incidences was found
between individuals with high and low ASI values. The
association between ASI and non-CVD mortality appears to
be driven by both cancer mortality and mortality by other
causes. To our knowledge, increased ASI has not previously
been found to predict cancer mortality. The origin of this
association should be subject to future research. Unlike ASI,
and in contrast to previous reports of studies in 9431 (65–
102 years old)40 and 2725 (20–80 years old)41 individuals
Table 4. Reclassiﬁcation of Predicted 5.9-Year Risk of New-Onset CVD Events With the Addition of PP to a Non–Laboratory-Based
Framingham Risk Score
Model Without PP
Model With PP Risk Reclassiﬁcation
<5% 5% to 15% ≥15% Total Higher Lower
<5%
Persons included 14 588 1324 0 15 912
No. of events 376 44 0 420 44 NA
No. of nonevents 14 212 1280 0 15 492 1280 NA
5%–15%
Persons included 7198 64 609 3198 75 005
No. of events 305 6055 666 7026 666 305
No. of nonevents 6893 58 554 2532 67 979 2532 6893
≥15%
Persons included 0 4507 46 147 50 654
No. of events 0 477 10 267 10 744 NA 477
No. of nonevents 0 4030 35 880 39 910 NA 4030
Total
Persons included 21 786 70 440 49 345 141 571
No. of events 681 6576 10 933 18 190 710 782
No. of nonevents 21 105 63 864 38 412 123 381 3812 10 923
NRI 5.4% (95% CI: 4.9–5.8; P<0.001)
CI indicates conﬁdence interval; CVD, cardiovascular disease; NA, not applicable; NRI, net reclassiﬁcation improvement; PP, pulse pressure.
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from the general population, PP was not convincingly
associated with all-cause or non-CVD mortality.
Heart Rate
The addition of heart rate to the ASI models had little effect,
suggesting that heart rate had no confounding effect on ASI,
unlike previously suggested for aortic PWV.25,26 The addition
of heart rate to the PP models had similar little effect, arguing
against a need for heart rate adjustment for PP.24 It is
interesting that heart rate was inversely associated with PP,
whereas it was positively associated with ASI. However, it
should be noted that the effect of heart rate is small for both
measures, also when compared with the effects of the other
characteristics in Table 1.
Strengths and Limitations
The associations between ASI and PP with disease and
mortality outcomes have been studied previously but our
contemporary study is unique. Not only is the very large
sample size unprecedented, but also we provide a community-
based population with both ASI and PP measurements in
combination with detailed health- and mortality-related data.
Although the effect sizes were small to moderate for most
outcomes in the unadjusted Cox regression analyses and even
smaller in the adjusted analyses, the large sample size
allowed us to detect these at the statistically signiﬁcant level.
One important limitation is the limited duration of disease
follow-up. A second limitation is that, although we could
adjust for a number of important classical risk factors, we did
not have data available on serum lipid levels to take into
account in our multivariable models. A third limitation is that
the accuracy of Hospital Episode Statistics data used for our
analyses is not known for most data ﬁelds. Furthermore, the
methodological differences of arterial stiffness measurement
(aortic PWV versus ASI) are likely to play a role in the
discrepancies found between our and previous studies. ASI
derived by ﬁnger photoplethysmography is inﬂuenced by the
elasticity of the large central arteries and the properties of the
reﬂection sites, both central and peripheral.16,25 In addition,
the PWV measured in the peripheral arteries are usually
higher than the aortic PWV because of the nearer reﬂection
sites.25 These differences make results from our and previous
studies (aortic PWV) more difﬁcult to directly compare. Finally,
brachial PP was used as a measure for systemic arterial
stiffness instead of central PP, which is measured at the
carotid artery. Brachial PP is generally higher than central PP
because of the larger number of reﬂection sites in the
peripheral arteries compared with the central arteries. The
central arteries of younger individuals are more elastic than
the peripheral arteries, which can further increase difference
between brachial PP and central PP, and might have resulted
in an overestimation of the stiffness of their arterial tree.7
Perspectives
Higher ASI is associated with cardiovascular risk factors and
is an independent predictor of new-onset CVD outcomes as
well as all-cause, CVD, and non-CVD mortality. Although ﬁnger
photoplethysmography is a simple and fast method, ASI
measurement added relatively little to the risk prediction in










Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
ASI
Model 1 1.26 (1.23–1.30) <0.001 1.35 (1.28–1.42) <0.001 1.22 (1.18–1.27) <0.001
Model 2 1.09 (1.05–1.12) <0.001 1.11 (1.05–1.18) <0.001 1.07 (1.03–1.12) <0.001
Model 3 1.08 (1.04–1.11) <0.001 1.10 (1.04–1.16) 0.001 1.07 (1.03–1.11) <0.001
Model 4 1.08 (1.05–1.12) <0.001 1.11 (1.05–1.17) <0.001 1.07 (1.03–1.11) <0.001
PP
Model 1 1.32 (1.28–1.36) <0.001 1.47 (1.40–1.55) <0.001 1.25 (1.21–1.30) <0.001
Model 2 1.01 (0.97–1.04) 0.66 1.08 (1.02–1.14) 0.01 0.98 (0.94–1.02) 0.25
Model 3 1.05 (1.00–1.09) 0.04 1.15 (1.06–1.23) <0.001 1.00 (0.95–1.05) 0.94
Model 4 1.03 (0.99–1.08) 0.17 1.10 (1.02–1.18) 0.02 1.00 (0.95–1.05) 0.94
Hazard ratios with 95% conﬁdence interval (CI) estimated using ASI per SD change in m/s and PP per SD change in mm Hg are shown per model for all-cause, CVD, and non-CVD mortality.
Model 1: univariate (unadjusted). Model 2: adjusted for age and sex. Model 3: Model 2+mean arterial pressure, diabetes mellitus, smoking, and body mass index. Model 4: Model 3+history
of CVD, myocardial infarction, coronary heart disease, heart failure, and stroke. ASI indicates arterial stiffness index; CVD, cardiovascular disease; PP, pulse pressure.
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this community-based population, limiting its potential clinical
value. Similar to ASI, PP was an independent predictor of new-
onset CVD outcomes and CVD mortality. PP improved the
CVD risk prediction classiﬁcation by 5.4%, suggesting that PP
could be used as a clinical tool to improve risk prediction for
disease outcomes in patients. Also similar to ASI, PP is
obtained with minimal efforts, further favoring the use of PP
over ASI in clinical settings. ASI may, however, remain an
interesting measure for studying vascular aging and stiff-
ness.42
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Variable definitions constructed using ICD-9, ICD-10 and OPCS-4 codes as well as self-reported data fields with disease- or procedure-specific codes between brackets are shown.  
Abbreviations: ICD, International Classification of Diseases; OPCS, Office of Population, Censuses and Surveys: Classification of interventions and Procedures
Table S1. Variable definitions used in UK Biobank 
Variable ICD-9 ICD-10 OPCS-4 Self-reported fields 
Cardiovascular disease 3361, 36231, 36232, 39-44 I00-I78, G951, H341, H342, O10, S066, 
Z951, Z955 
A052-A054, K01, K02, K04, K07, K09-
K14, K18-K31, K33-K35, K37, K38, K40-
K50, K52-K55, K571-K576, K621-K623, 
K64, K68, K75, K77, L16, L18-L23, L25, 
L263, L265, L266, L268-L301, L303, 
L304, L311, L313, L314, L33-L351, 
L353, L355, L37-L381, L383, L384, 
L391, L392, L395, L41, L421, L424, 
L428-L432, L435, L45, L461, L464, 
L471, L474, L48-L542, L544, L56-L632, 
L635, L638, L639, L651-L653, L661, 
L662, L665, L667, L68, L701, L705, 
L711, L712, L715-L717, O01-O03, X503, 
X504, X508, X509 
3267, 4056, 5529(1), 5540(1), 6150(2,3), 
20002(1067, 1074-1079, 1081, 1082, 
1086, 1087, 1425, 1426, 1471, 1479, 
1483-1492, 1583-1591), 20004(1069, 
1070, 1095, 1097-1103, 1108, 1523, 
1553) 
Coronary heart disease 410, 412, 414 I21-25, Z951, Z955 K40-K46, K49, K50, K75 6150(1), 3894, 20004(1070, 1095, 1523) 
Myocardial infarction 410, 412 I21-I23, I252  20002(1075) 
Heart failure 428 I110, I130, I132, I50  20002(1076) 
Hypertension 401-405 I10-I13, I15, O10  2966, 6150(4), 6153(2), 6177(2), 
20002(1065, 1072) 
Stroke 3361, 36231, 36232, 430, 431, 4329, 
43301, 43311, 43321, 43331, 43381, 
43391, 434, 436 
I60, I61, I629, I63, I64, I678, I690, I693, 
G951, H341, H342, S066 
A052-A054, L351, L353, L343 6150(3), 4056, 20002(1081, 1491,  1583, 
1086) 
Diabetes mellitus 250 E10-E14  2976, 6153(3), 6177(3), 20002(1220, 
1222, 1223) 
Hyperlipidemia 272 E78  6153(1), 6177(1), 1473 
Cancer 21-23, 141, 142, 144, 146, 150-157, 159-
162, 164, 170-174, 179, 180, 182-191, 
193, 195, 196, 198-202, 204, 205, V10 
C00-C96, D00-D48, Z85  20001 









Means with Standard Deviation (SD) or counts with percentages are given per 
characteristic.  











Mean±SD or n (%) Mean±SD or n (%) 
Males 77,708 (45.8) 151,470 (45.5) 
Age, y 56.77±8.16  56.41±8.06  
Heart rate, bpm 68.72±11.01 69.84±11.31 
Body mass index, kg/m2 
Systolic blood pressure, mm Hg 







Mean arterial pressure, mm Hg 98.94±10.65 99.24±10.93 
Hypertension 52,885 (31.2) 102,330 (30.7) 
Diabetes 10,267 (6.1) 17,591 (5.3) 
Hyperlipidemia 34,723 (20.5) 61,306 (18.4) 
Past or current smoker 100,590 (59.3) 198,302 (59.5) 
Ethnicity   
 White 153,931 (90.8) 318,898 (95.8) 
 Asian 6,586 (3.9) 4,870 (1.5) 
 Black 4,508 (2.7) 3,558 (1.1) 
 Mixed 1,294 (0.8) 1.664 (0.5) 
 Other/Unknown 3,294 (1.9) 4,052 (1.2) 










Table S3. The independent association of ASI and PP with disease 
 Cardiovascular Disease 
ntotal=141,571 
nevent=18,190 (12.8%) 
 Myocardial Infarction 
ntotal=165,589 
nevent=1,587 (1.0%) 
 Coronary Heart Disease 
ntotal=162,543 
nevent=4,326 (2.7%) 
HR (95%CI) P value  HR (95%CI) P value  HR (95%CI) P value 
ASI 
   Model 3 
   Model 3* 
 
1.04 (1.03 to 1.06) 








1.13 (1.07 to 1.18) 








1.08 (1.05 to 1.11) 





   Model 3 
   Model 3† 
 
1.05 (1.03 to 1.07) 








1.11 (1.04 to 1.19) 








1.14 (1.09  to 1.18) 































Hazard ratios (HR) with 95% Confidence Interval (CI) estimated using ASI per SD change in m/s and PP per SD change in mm Hg 
are shown for cardiovascular disease, myocardial infarction, coronary heart disease, heart failure and stroke. Shown are the 
outcomes for the largest significant model and additional adjustment for PP or ASI. Model 2: Adjusted for age and sex. Model 3: 
Model 2 + mean arterial pressure, diabetes, smoking and BMI.  
Abbreviations: ASI, Arterial Stiffness Index; NA, Not Applicable; PP, Pulse Pressure 
* Additionally adjusted for PP 
† Additionally adjusted for ASI 
Table S3. Continued 
 Heart Failure 
ntotal=168,751 
nevent=1,192 (0.7%) 
 Stroke  
ntotal=166,954 
nevent=1,319 (0.8%) 
HR (95%CI) P value  HR (95%CI) P value 
ASI 
   Model 3 
   Model 3* 
 
1.07 (1.01 to 1.13) 








1.08 (1.02 to 1.14) 





   Model 3 
   Model 3† 
 
1.21 (1.13 to 1.30) 








1.16 (1.10 to 1.22) 














Table S4. Harrell’s C-indices and post estimation analyses of models for risk prediction of disease and mortality with and 







Coronary Heart Disease 
ntotal=162,543 
nevent=4,326 (2.7%) 





P value Harrell’s 
C-index 
P value Harrell’s 
C-index 




   Model 3+ASI 
   Model 3–ASI 
   Model 3+PP+ASI 






































   Model 3+PP 
   Model 3–PP 
   Model 3+ASI+PP 














































Harrell’s C-indices are given for models with (+) and without (-) ASI or PP and for models with ASI or PP with or without additional 
adjustment for PP or ASI respectively. Post estimation analysis P values for the difference between the predictive values of the 
models are given. Model 3: adjusted for age, sex, mean arterial pressure, diabetes, smoking and body mass index. Model 4: Model 
3 + history of CVD, myocardial infarction, coronary heart disease, heart failure and stroke.  
Abbreviations: ASI, Arterial Stiffness Index; CVD, Cardiovascular Disease; PP, Pulse Pressure. * Results are given for Model 4 
instead of Model 3.   
Table S4. Continued.  














P value Harrell’s 
C-index 
P value Harrell’s 
C-index 




   Model 3+ASI 
   Model 3–ASI 
   Model 3+PP+ASI 







































   Model 3+PP 
   Model 3–PP 
   Model 3+ASI+PP 















































Hazard ratios with 95% Confidence Interval (CI) estimated using ASI per SD change in m/s are shown per model for non-CVD/non-
cancer and non-CVD cancer mortality. Model 1: Univariate (unadjusted). Model 2: Adjusted for age and sex. Model 3: Model 2 + 
mean arterial pressure, diabetes, smoking and body mass index, Model 4: Model 3 + history of CVD, myocardial infarction, coronary 
heart disease, heart failure, and stroke. 
Abbreviations: ASI, Arterial Stiffness Index; CVD, Cardiovascular Disease. 
  
Table S5. Association of ASI with non-CVD/non-cancer and non-CVD cancer mortality 
 Non-CVD/Non-Cancer mortality 
ntotal=169,613 
nevent=465 (0.3%) 
Non-CVD Cancer mortality 
ntotal=169,613 
nevent=2,033 (1.2%) 
Hazard Ratio (95%CI) P value Hazard Ratio (95%CI) P value 
ASI 
   Model 1 
   Model 2 
   Model 3 
   Model 4 
 
1.25 (1.15 to 1.36) 
1.10 (1.01 to 1.20) 
1.12 (1.02 to 1.22) 







1.22 (1.17 to 1.27) 
1.07 (1.02 to 1.12) 
1.06 (1.02 to 1.11) 















Hazard ratios (HR) with 95% Confidence Interval (CI) estimated using ASI per SD change in m/s and PP per SD change in mm Hg 
are shown for all-cause, CVD and non-CVD mortality. Shown are the outcomes for the largest significant model and additional 
adjustment for PP or ASI. Model 1: Univariate (unadjusted). Model 3: Adjusted for age, sex, mean arterial pressure, smoking and 
body mass index. Model 4: Model 3 + history of CVD, myocardial infarction, coronary heart disease, heart failure and stroke.  
Abbreviations: ASI, Arterial Stiffness Index; CVD, Cardiovascular Disease; PP, Pulse Pressure 
* Additionally adjusted for PP 
† Additionally adjusted for ASI 
  
Table S6. Independent association of ASI and PP with mortality 
 All-cause Mortality 
ntotal=169,613 
nevent=3.678 (2.2%) 
 CVD Mortality 
ntotal=169,613 
nevent=1,180 (0.7%) 
 Non-CVD Mortality 
ntotal=169,613 
nevent=2,498 (1.5%) 
HR (95%CI) P value  HR (95%CI) P value  HR (95%CI) P value 
ASI 
  Model 4 
  Model 4* 
 
1.08 (1.05 to 1.12) 








1.11 (1.05 to 1.17) 








1.07 (1.03 to 1.11) 





  Model 3 
  Model 3† 
 
1.05 (1.00 to 1.09) 








1.10 (1.02 to 1.18) 








1.25 (1.21 to 1.30) 













Table S7. Association of ASI and PP with diseases and mortality, additionally adjusted for heart rate 
 Cardiovascular Disease 
ntotal=141,571 
nevent=18,190 (12.8%) 
 Myocardial Infarction 
ntotal=165,589 
nevent=1,587 (1.0%) 
 Coronary Heart Disease 
ntotal=162,543 
nevent=4,326 (2.7%) 
HR (95%CI) P value  HR (95%CI) P value  HR (95%CI) P value 
ASI 
   Model 3 
   Model 3* 
 
1.04 (1.03 to 1.06) 








1.13 (1.07 to 1.18) 








1.08 (1.05 to 1.11) 





   Model 3 
   Model 3* 
 
1.05 (1.03 to 1.07) 








1.11 (1.04 to 1.19) 








1.14 (1.09  to 1.18) 














Table S7. Continued. 






 All-cause Mortality 
ntotal=169,613 
nevent=3.678 (2.2%) 
HR (95%CI) P value  HR (95%CI) P value  HR (95%CI) P value 
ASI 
   Model 3 
   Model 3* 
 
1.07 (1.01 to 1.13) 








1.08 (1.02 to 1.14) 








1.08 (1.05 to 1.12) 





   Model 3 
   Model 3* 
 
1.21 (1.13 to 1.30) 








1.16 (1.10 to 1.22) 








1.05 (1.00 to 1.09) 
























Hazard ratios (HR) with 95% Confidence Interval (CI) estimated using ASI per SD change in m/s and PP per SD change in mm Hg 
are shown for disease and mortality outcomes. Shown are the outcomes for the largest significant model and additional adjustment 
for heart rate. Model 1: Univariate (unadjusted). Model 3: adjusted for age, sex, mean arterial pressure, diabetes, smoking and BMI. 
Model 4: Model 3 + history of cardiovascular disease, myocardial infarction, coronary heart disease, heart failure and stroke.  
Abbreviations: ASI, Arterial Stiffness Index; PP, Pulse Pressure 
* Additionally adjusted for heart rate 
  
Table S7. Continued. 
 CVD Mortality 
ntotal=169,613 
nevent=1,180 (0.7%) 
 Non-CVD Mortality 
ntotal=169,613 
nevent=2,498 (1.5%) 
HR (95%CI) P value  HR (95%CI) P value 
ASI 
   Model 4 
   Model 4* 
 
1.11 (1.05 to 1.17)  








1.07 (1.03 to 1.11) 





   Model 4 
   Model 4* 
 
1.10 (1.02 to 1.18) 








1.25 (1.21 to 1.30) 












Table S8. Harrell’s C-indices for ASI and PP in diabetics and non-diabetics 
    Harrell’s C index  
  Ntotal Nevent ASI PP P value 
No Diabetes Cardiovascular Disease 135,502 16,298 0.718 0.718 0.86 
 Myocardial Infarction 156,206 1,351 0.733 0.730 0.02 
 Coronary Heart Disease 153,803 3,722 0.718 0.717 0.56 
 Heart Failure 158,704 929 0.753 0.753 0.84 
 Stroke 157,124 1,129 0.706 0.706 0.77 
 All-cause mortality 159,346 3,152 0.698 0.697 <0.05 
 CVD mortality 159,346 921 0.759 0.757 0.21 
 Non-CVD mortality 159,346 2,231 0.676 0.674 0.10 
Diabetes Cardiovascular Disease 6,069 1,892 0.620 0.623 0.02 
 Myocardial Infarction 9,383 236 0.650 0.671 0.12 
 Coronary Heart Disease 8,740 604 0.626 0.635 0.09 
 Heart Failure 10,047 263 0.705 0.711 0.37 
 Stroke 9,830 190 0.643 0.641 0.67 
 All-cause mortality 10,267 526 0.657 0.661 0.25 
 CVD mortality 10,267 259 0.687 0.702 0.09 
 Non-CVD mortality 10,267 267 0.631 0.631 0.93 
Harrell’s C-indices for the largest model (Model 3 for disease and Model 4 for mortality outcomes) per subgroup. Abbreviations: 
ASI, Arterial Stiffness Index; PP, Pulse Pressure 








Table S9. Harrell’s C-indices for ASI and PP in participants with and without hypertension 
    Harrell’s C index  
  Ntotal Nevent ASI PP P value 
No Hypertension Cardiovascular Disease 110,417 7,754 0.712 0.711 0.39 
 Myocardial Infarction 116,307 754 0.742 0.740 0.10 
 Coronary Heart Disease 115,878 1,982 0.732 0.731 0.27 
 Heart Failure 116,678 400 0.763 0.762 0.81 
 Stroke 115,887 621 0.708 0.708 0.75 
 All-cause mortality 116,728 1,870 0.694 0.693 0.11 
 CVD mortality 116,728 428 0.756 0.755 0.56 
 Non-CVD mortality 116,728 1,442 0.679 0.677 0.12 
Hypertension Cardiovascular Disease 31,154 10,436 0.600 0.600 0.52 
 Myocardial Infarction 49,282 833 0.679 0.677 0.40 
 Coronary Heart Disease 46,665 2,344 0.649 0.650 0.72 
 Heart Failure 52,073 792 0.705 0.706 0.62 
 Stroke 51,067 698 0.654 0.654 0.70 
 All-cause mortality 52,885 1,808 0.680 0.680 0.80 
 CVD mortality 52,885 752 0.729 0.730 0.74 
 Non-CVD mortality 52,885 1,056 0.648 0.647 0.34 
Harrell’s C-indices for the largest model (Model 3 for disease and Model 4 for mortality outcomes) per subgroup. Abbreviations: 
ASI, Arterial Stiffness Index; PP, Pulse Pressure 








Table S10. Harrell’s C-indices for ASI and PP in participants younger or older than the median 56.8 years 
    Harrell’s C index  
  Ntotal Nevent ASI PP P value 
Young (≤56.8 y) Cardiovascular Disease 67,821 4,843 0.735 0.735 0.02 
 Myocardial Infarction 73,782 367 0.743 0.736 0.06 
 Coronary Heart Disease 73,355 947 0.733 0.731 0.21 
 Heart Failure 74,306 189 0.739 0.735 0.59 
 Stroke 73,737 248 0.647 0.645 0.54 
 All-cause mortality 74,468 737 0.656 0.648 0.03 
 CVD mortality 74,468 192 0.729 0.717 0.16 
 Non-CVD mortality 74,468 545 0.636 0.630 0.15 
Old (>56.8 y) Cardiovascular Disease 73,750 13,347 0.660 0.662 <0.01 
 Myocardial Infarction 91,807 1,220 0.694 0.692 0.40 
 Coronary Heart Disease 89,188 3,379 0.662 0.663 0.19 
 Heart Failure 94,445 1,003 0.716 0.716 0.85 
 Stroke 93,217 1,071 0.653 0.653 0.96 
 All-cause mortality 95,145 2,941 0.653 0.652 0.33 
 CVD mortality 95,145 988 0.730 0.729 0.32 
 Non-CVD mortality 95,145 1,953 0.617 0.616 0.34 
Harrell’s C-indices for the largest model (Model 3 for disease and Model 4 for mortality outcomes) per subgroup. Abbreviations: 
ASI, Arterial Stiffness Index; PP, Pulse Pressure 








Table S11. Harrell’s C-indices for ASI and PP in participants with lower or higher FRS than the median 
    Harrell’s C index  
  Ntotal Nevent ASI PP P value 
FRS ≤9.29 Cardiovascular Disease 78,122 5,536 0.706 0.706 0.12 
 Myocardial Infarction 85,473 303 0.669 0.666 0.50 
 Coronary Heart Disease 85,039 971 0.685 0.684 0.47 
 Heart Failure 85,849 213 0.720 0.723 0.48 
 Stroke 85,240 336 0.659 0.657 0.39 
 All-cause mortality 85,974 963 0.654 0.650 0.10 
 CVD mortality 85,974 189 0.684 0.678 0.18 
 Non-CVD mortality 85,974 774 0.650 0.648 0.31 
FRS >9.29 Cardiovascular Disease 63,449 12,654 0.648 0.649 0.14 
 Myocardial Infarction 80,116 1,284 0.646 0.642 0.15 
 Coronary Heart Disease 77,504 3,355 0.634 0.634 0.83 
 Heart Failure 82,902 979 0.699 0.699 0.95 
 Stroke 81,714 983 0.655 0.655 0.85 
 All-cause mortality 83,639 2,715 0.658 0.657 0.54 
 CVD mortality 83,639 991 0.705 0.703 0.28 
 Non-CVD mortality 83,639 1,724 0.635 0.635 0.77 
Harrell’s C-indices for the largest model (Model 3 for disease and Model 4 for mortality outcomes) per subgroup. The FRS is 
calculated for a max of 5.92 years. Abbreviations: ASI, Arterial Stiffness Index; FRS, Framingham Risk; PP, Pulse Pressure 








Table S12. Harrell’s C-indices for ASI and PP in men and women separately 
    Harrell’s C index  
  Ntotal Nevent ASI PP P value 
Women Cardiovascular Disease 79,310 8,710 0.723 0.724 0.001 
 Myocardial Infarction 91,040 439 0.704 0.701 0.38 
 Coronary Heart Disease 90,117 1,500 0.711 0.713 0.11 
 Heart Failure 91,704 404 0.753 0.760 0.04 
 Stroke 90,785 545 0.702 0.703 0.41 
 All-cause mortality 91,905 1,431 0.679 0.677 <0.05 
 CVD mortality 91,905 327 0.734 0.733 0.50 
 Non-CVD mortality 91,905 1,104 0.664 0.662 0.08 
Men Cardiovascular Disease 62,261 9,480 0.713 0.713 0.04 
 Myocardial Infarction 74,549 1,148 0.670 0.667 0.22 
 Coronary Heart Disease 72,426 2,826 0.680 0.680 0.63 
 Heart Failure 77,047 788 0.748 0.745 0.15 
 Stroke 76,169 774 0.702 0.702 0.49 
 All-cause mortality 77,708 2,247 0.700 0.699 0.32 
 CVD mortality 77,708 853 0.742 0.741 0.57 
 Non-CVD mortality 77,708 1,394 0.675 0.674 0.36 
Harrell’s C-indices for the largest model (Model 3 for disease and Model 4 for mortality outcomes) per subgroup. Abbreviations: 
ASI, Arterial Stiffness Index; PP, Pulse Pressure









Figure S1. Shown are the in- and exclusion criteria for the sample selection strategy 
used in our analyses. Abbreviations: ASI, Arterial Stiffness Index; PP, Pulse Pressure; 
SD, Standard Deviation 
  









Figure S2. Shown are regression spline models in which the red line with gray colored 
95% Confidence Intervals (CI) represents the linear regression of ASI and Pulse 
Pressure over increasing age (per 5 years) for men and women separately. 
Abbreviation: ASI, Arterial Stiffness Index 

























Figure S3. Shown are cumulative new-onset myocardial infarction, coronary heart disease, heart failure and stroke in (%) divided by 
the median ASI. All curves were adjusted for age and sex. Log-Rank testing shows significant differences for both myocardial 
infarction and coronary heart disease. Abbreviations: ASI, Arterial Stiffness index 
























Figure S4. Shown are cumulative new-onset myocardial infarction, coronary heart disease and stroke in (%) divided by the median 
PP. All curves were adjusted for age and sex. Log-Rank testing shows significant differences for all. Abbreviations: PP, Pulse 
Pressure 








Figure S5. Shown are risk of overall cardiovascular disease for quintiles of arterial stiffness index and pulse pressure separately. 
The analyses were adjusted for age, sex, mean arterial pressure, diabetes, body mass index and smoking. Abbreviations: ASI, 
Arterial Stiffness Index; PP, Pulse Pressure  








Figure S6. Shown are cumulative all-cause, CVD and non-CVD mortality in (%) divided by the median ASI. All curves were adjusted 
for age and sex. Log-Rank testing shows significant differences for all-cause and non-CVD, but not CVD mortality. Abbreviations: 
ASI, Arterial Stiffness Index; CVD, Cardiovascular Disease








Figure S7. Shown is the cumulative CVD-mortality in (%) divided by the median PP. 
The curve was adjusted for age and sex. Log-Rank testing shows a significant 
difference. Abbreviations: PP, Pulse Pressure; CVD, Cardiovascular Disease 






M. Abdullah Said, Ruben N. Eppinga, Erik Lipsic, Niek Verweij and Pim van der Harst
Mortality
Relationship of Arterial Stiffness Index and Pulse Pressure With Cardiovascular Disease and
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.007621
2018;7:e007621; originally published January 22, 2018;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/7/2/e007621
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on January 24, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
